TAIKO PHARMACEUTICAL CO.,LTD. FY2026 Q2 Earnings Report

Quick View

Executive Summary

Although revenue increased in Q2 of FY2026 (the first half), profitability from the core business deteriorated, resulting not in higher operating income but in a substantial decline. Revenue grew to ¥2.64B (¥2.41B in the previous year, YoY +9.3%), but the increase in SG&A expenses offset the benefit of higher revenue, reducing operating income to ¥0.02B (¥0.05B in the previous year, YoY -63.4%). Ordinary income improved to ¥0.04B (YoY +101.4%), supported by non-operating income such as interest income and foreign exchange gains. However, extraordinary income, including gains on the sale of investment securities, recorded in the same period of the previous year (¥0.36B) was absent in the current period, resulting in a substantial decline in net income to ¥0.04B (¥0.28B in the previous year, YoY -84.2%). The key point of this earnings result is that the company’s core profit structure is weakening beneath the revenue increase.

Factors Affecting Performance

【Revenue】Revenue increased to ¥2.64B, up +9.3% year on year. While the core Pharmaceuticals Business led overall performance with revenue of ¥2.52B (+14.4%, composition ratio 95.8%), the Infection Control Business contracted to ¥0.11B (-45.3%, composition ratio 4.2%), resulting in a greater concentration of the business portfolio.

【Profit and Loss】The gross profit margin remained high at 50.8%, but SG&A expenses increased to ¥1.32B (SG&A ratio 50.1%), nearly offsetting the increase in revenue. Segment income in the Pharmaceuticals Business declined to ¥0.56B (-7.3%), while the Infection Control Business continued to report a loss of ¥-0.09B (the loss narrowed by +39.1% year on year), leaving company-wide operating income at only ¥0.02B (YoY -63.4%). Ordinary income improved to ¥0.04B (YoY +101.4%) due to non-operating income, including foreign exchange gains of ¥0.01B, but net income declined to ¥0.04B (YoY -84.2%) due to the absence of extraordinary income recorded in the previous year, including a ¥0.35B gain on the sale of investment securities. The results reflect higher revenue but lower profit, with dilution of the earnings structure emerging as a clear trend.

Segment Analysis

The Pharmaceuticals Business recorded revenue of ¥2.52B (+14.4%), segment income of ¥0.56B (-7.3%), and a profit margin of 22.1%, indicating a slight decline in profitability despite higher revenue. The Infection Control Business recorded revenue of ¥0.11B (-45.3%), a segment loss of ¥-0.09B (the loss narrowed by +39.1% year on year), and a profit margin of -82.9%, demonstrating continued structural losses. The Pharmaceuticals Business accounts for 95.8% of revenue and all segment income, while losses in the Infection Control Business continue to depress the company-wide profit margin. In the Infection Control Business, an impairment loss (an immaterial amount) was recorded for fixed assets for which recoverability was not deemed probable.

Key Financial Metrics

【Profitability】The operating margin declined significantly to 0.6% from the previous year (equivalent to 190bp), while the net profit margin remained at only 1.7%. ROE was 0.5%, primarily due to the decline in the net profit margin, while total asset turnover of 0.238x and financial leverage of 1.32x remained broadly stable.【Cash Quality】Operating Cash Flow (OCF) was ¥-0.07B, below net income of ¥0.04B, indicating challenges in cash generation.【Investment Efficiency】Capital expenditures were ¥0.18B, and free cash flow was ¥-0.75B, indicating that cash generation remained below investment and shareholder returns.【Financial Soundness】The equity ratio remained high at 76.0%, and short-term solvency was strong, with current assets of ¥7.20B compared with current liabilities of ¥1.40B. Cash and deposits decreased substantially year on year to ¥2.67B, primarily due to repayment of long-term borrowings (financing CF ¥-0.85B).

Cash Flow Analysis

Operating CF was ¥-0.07B, remaining below net income of ¥0.04B. An increase in inventories (¥-0.29B) and a decrease in the provision for bonuses pressured operating CF, while a decrease in trade receivables (¥+0.53B) contributed positively. Investing CF was ¥-0.68B, including capital expenditures of ¥0.18B and a transfer to time deposits (¥0.50B). Financing CF was ¥-0.85B, primarily due to repayment of long-term borrowings (¥0.67B). As a result, free cash flow (operating CF + investing CF) was ¥-0.75B, and cash and deposits declined to ¥2.67B. Cash generation from operating activities has not kept pace with improvements in earnings, making inventory and working capital management a challenge from a funding-efficiency perspective.

Quality of Earnings

There were no extraordinary gains or losses in the current period, and the absence of extraordinary income of ¥0.36B, including the ¥0.35B gain on the sale of investment securities recorded in the same period of the previous year, made the year-on-year decline in net income appear substantial. Non-operating income was ¥0.03B, equivalent to approximately 1% of revenue, and primarily consisted of interest income and foreign exchange gains. Accordingly, the relative contribution of the ¥0.01B foreign exchange gain was significant compared with operating income of ¥0.02B. Operating CF was below net income, indicating a gap between reported earnings and actual cash generation, primarily due to working capital factors such as the increase in inventories. The difference between ordinary income and net income was small, and the impact of tax effects was limited.

Earnings Forecasts and Guidance

Progress against the full-year plan (revenue of ¥7.20B, operating income of ¥0.50B, and ordinary income of ¥0.52B) was 36.6% for revenue, 3.4% for operating income, and 7.9% for ordinary income in the first half. Compared with a simple 50% time-apportionment benchmark, all figures were below target, with the delays in operating income and ordinary income particularly pronounced. The company has not revised either its earnings forecast or dividend forecast, and the plan assumes back-half-weighted progress, including the containment of SG&A expenses and a reduction in losses in the Infection Control Business during the second half.

Shareholder Returns

The interim dividend at the end of Q2 was zero. The full-year dividend forecast is ¥3.5 per share. Based on the full-year net income forecast of ¥0.55B and the average number of shares outstanding during the period (approximately 50.28M shares), the annual total dividend is calculated at approximately ¥0.18B, implying a payout ratio of approximately 32%. The dividend forecast has not been revised. Given that current free cash flow is ¥-0.75B, cash generation during the second half will be a key factor in assessing the company’s ability to execute its annual dividend plan.

Risk Factors

1. Business Portfolio Concentration Risk: The Pharmaceuticals Business accounts for 95.8% of revenue, indicating a high degree of dependence on a single business. The Infection Control Business has contracted to revenue of ¥0.11B (-45.3% year on year), while its segment loss of ¥-0.09B continues.

2. Weak Cash Generation: Operating CF of ¥-0.07B was below net income of ¥0.04B, and free cash flow was negative at ¥-0.75B. Deterioration in working capital, including the increase in inventories, is pressuring cash flow.

3. Dilution of Profitability: The operating margin declined to 0.6%, with the increase in SG&A expenses offsetting the benefit of higher revenue. An impairment loss (an immaterial amount) was also recorded on fixed assets in the Infection Control Business.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (pharma)

Profitability and Returns

Although median data for the industry was not obtained, the company’s operating margin of 0.6% and net profit margin of 1.7% appear to be at the low end relative to typical pharmaceutical companies.

Growth and Capital Efficiency

The revenue growth rate of 9.3% indicates a trend of increasing revenue, but comparison with profit margins suggests that growth has not translated into earnings.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Despite higher revenue, the operating margin declined to 0.6%, with the increase in SG&A expenses offsetting the benefit of higher revenue. Continued losses in the Infection Control Business are also depressing overall profitability.

2. Operating CF was below net income, and free cash flow was negative. Working capital movements, centered on the increase in inventories, created a gap between reported earnings and cash generation.

3. First-half progress against the full-year plan was 36.6% for revenue and 3.4% for operating income, with the delay in operating income particularly significant. The company has not revised its earnings forecast, and the extent to which profitability improves in the second half will be a key point to monitor in future earnings results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥151–¥159 at cost of equity ±1%, and ¥155–¥155 at ω±0.1.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest Rate Reference Month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---